Skip to main content
. 2021 Nov 26;11(12):1298. doi: 10.3390/life11121298

Figure 5.

Figure 5

LIF/LIFR signaling pathway as a target to prevent breast cancer stemness. (a,b) qRT-PCR analysis of the stem cell marker Nanog and Oct4 expression in MCF7 and MBA-MB-231 cells treated with CAF-CM or CAF-CM in combination with anti-LIFR Ab after 7 days. qRT-PCR analysis of Nanog and Oct4 expression in MCF7 and MBA-MB-231 cells treated with LIF (25 ng ml) or LIF in combination with anti-LIFR Ab after 7 days. Representative graphs of 3 independent experiments using the same CAF-CM are shown. The data show the mean ± S.D. and were analyzed using the Student’s t-test; * p < 0.05, ** p < 0.01, and *** p < 0.001. (c) Breast stem cell markers (CD24−/CD44+) were analyzed by flow cytometry in MCF7 (CD24+/CD44−) and MDA-MB-231 (CD24−/CD44+) cells after 4 and 7 days. (Percentage of positive CD24−/CD44+ population is shown in numbers for MCF7, and the mean fluorescence intensity (MFI) is shown in numbers for MDA-MB-231).